{"id":18826,"date":"2022-09-09T17:51:33","date_gmt":"2022-09-09T12:21:33","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=18826"},"modified":"2022-09-29T11:43:09","modified_gmt":"2022-09-29T06:13:09","slug":"promising-alopecia-areata-treatment-options","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options","title":{"rendered":"Alopecia Areata Treatment: Which Pipeline Therapy Will Steal the Spotlight?"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d60c63a45f2\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d60c63a45f2\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options\/#FDA_approves_new_systemic_alopecia_areata_treatment\" >FDA approves new systemic alopecia areata treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options\/#Upcoming_potential_therapies_for_alopecia_areata_treatment\" >Upcoming potential therapies for alopecia areata treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options\/#Changing_alopecia_areata_treatment_trajectory\" >Changing alopecia areata treatment trajectory<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options\/#Coverage_policies_must_ensure_access_to_FDA-approved_alopecia_areata_treatments\" >Coverage policies must ensure access to FDA-approved alopecia areata treatments<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options\/#Future_perspective_in_the_alopecia_areata_treatment\" >Future perspective in the alopecia areata treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Currently, there is no cure and no FDA-approved treatments for alopecia. Thus, the alopecia areata treatment market is completely dominated by off-label drug therapies. Depending on the extent of hair loss and age, there are a variety of alopecia areata treatment options are available. The main goal of treatment is to block the immune system attack or stimulate the regrowth of hair. This can be effective, especially for people with milder forms of the disease.<\/p>\n\n\n\n<p>Moreover, approximately <strong>700,000<\/strong> people in the United States are diagnosed or affected by the alopecia areata, with just under half of these patients estimated to have complete scalp or total body baldness. This makes alopecia areata the second most common type of hair loss in the US, just behind pattern baldness or a receding hairline.<\/p>\n\n\n\n<p>Despite decreasing trends observed in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/alopecia-areata-epidemiology-forecast\">global burden of alopecia areata<\/a>, low-income countries and \u200b\u200bWestern Sub-Saharan Africa regions continue to exhibit rising incidence and disability-adjusted life-years rates. Alopecia areata affects <strong>2%<\/strong> of the general population and is a significant driver of psychological disorders such as depression, anxiety, and mental health distress.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164833\/alopecia-areata-treatment-1024x252.jpg\" alt=\"Alopecia Areata Market\" class=\"wp-image-18851\" width=\"1024\" height=\"252\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164833\/alopecia-areata-treatment-1024x252.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164833\/alopecia-areata-treatment-300x74.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164833\/alopecia-areata-treatment-150x37.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164833\/alopecia-areata-treatment-768x189.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164833\/alopecia-areata-treatment.jpg 1257w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption><strong>Alopecia Areata Patient Treatment Journey<\/strong><\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_approves_new_systemic_alopecia_areata_treatment\"><\/span><strong>FDA approves new systemic alopecia areata treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>With the limited number of alopecia areata treatment options available, many individuals with alopecia areata turned to wigs and false eyelashes. People with alopecia areata faced significant challenges as the disease is very stigmatizing. On <strong>June 13, 2022,<\/strong> Food and Drug Administration approved <strong>OLUMIANT (baricitinib)<\/strong> oral tablets to treat adult patients with severe alopecia areata aims at treating an entire body rather than the specific area being developed by <strong>Eli Lilly and Company and Incyte Corporation.<\/strong> Before the approval of <strong>Olumiant<\/strong>, there were zero <a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/alopecia-areata-market\">FDA-approved alopecia areata treatments<\/a>. This approval is huge, both for people with alopecia areata and the clinicians who have been advocating for them. It gives many patients better access to alopecia areata medication that can help them get their hair back and improve their quality of life.<\/p>\n\n\n\n<p>The recommended dose is <strong>OLUMIANT 2 mg\/day,<\/strong> with an increase to <strong>4 mg\/day<\/strong> if treatment response is inadequate. For patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4 mg\/day. Once an adequate response is achieved on 4 mg\/day, the dosage is to be decreased to 2 mg\/day. <strong>OLUMIANT <\/strong>is not recommended for use in combination with other <a href=\"https:\/\/www.delveinsight.com\/blog\/jak-inhibitors-market\">JAK inhibitors<\/a>, biologic immunomodulators, cyclosporine, or other potent immunosuppressants.<\/p>\n\n\n\n<p><strong>Eli Lilly and Company and Incyte Corporation,<\/strong> in May 2022, received a positive opinion for OLUMIANT (baricitinib) for the treatment of adults with severe alopecia areata from the European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP).<\/p>\n\n\n\n<p>The approval was based on <strong>Lilly&#8217;s BRAVE-AA1 and BRAVE-AA2 trials<\/strong>, the largest <strong>phase III<\/strong> alopecia areata clinical trial program, which evaluated the efficacy and safety of OLUMIANT in <strong>1,200<\/strong> adult patients with severe alopecia areata (\u226550% scalp hair loss as defined by a Severity of Alopecia Tool (SALT) score \u226550). Across the studies at <strong>36 weeks, 17-22%<\/strong> of patients taking <strong>OLUMIANT 2-mg\/day<\/strong> and <strong>32-35%<\/strong> of patients taking <strong>OLUMIANT 4-mg\/day <\/strong>achieved <strong>80%<\/strong> or more scalp hair coverage, compared to <strong>3-5%<\/strong> taking placebo. Additionally, <strong>11-13%<\/strong> of patients taking <strong>OLUMIANT 2-mg\/day<\/strong> and <strong>24-26%<\/strong> of patients taking<strong> OLUMIANT 4-mg\/day<\/strong> achieved<strong> 90%<\/strong> or more hair coverage, compared to <strong>1-4%<\/strong> of patients taking placebo; results for <strong>OLUMIANT 2-mg\/day<\/strong> were not statistically significant under the multiplicity control plan for <strong>BRAVE-AA2<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Upcoming_potential_therapies_for_alopecia_areata_treatment\"><\/span><strong>Upcoming potential therapies for alopecia areata treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Several leading giants such as <strong>Concert Pharmaceutical, Suzhou Zelgen Biopharmaceuticals, Pfizer, Legacy Healthcare, AnaptysBio, Reistone Biopharma, Eli Lilly and Company, Incyte Corporation, Novartis, Bioniz, Rigel Pharmaceuticals, Arcutis Biotherapeutics, LEO Pharma, Arena Pharmaceuticals, HCW Biologics<\/strong>, and others are currently developing novel alopecia areata therapies to improve the treatment space. Currently, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/alopecia-areata-pipeline-insight\">alopecia areata pipeline<\/a> looks promising with drug candidates including <strong>CTP-543, Jaktinib, Ritlecitinib, LH-8, ANB030, SHR0302<\/strong>, and others.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164632\/alopecia-areata-companies-1024x303.jpg\" alt=\"Alopecia Areata companies\" class=\"wp-image-18848\" width=\"1024\" height=\"303\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164632\/alopecia-areata-companies-1024x303.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164632\/alopecia-areata-companies-300x89.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164632\/alopecia-areata-companies-150x44.jpg 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164632\/alopecia-areata-companies-768x227.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164632\/alopecia-areata-companies.jpg 1205w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption><strong>Leading Players Involved in Developing Therapies for Alopecia Areata<\/strong><\/figcaption><\/figure>\n\n\n\n<p><strong>CTP-543<\/strong> is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 <strong>Breakthrough Therapy designation<\/strong> for moderate to severe alopecia areata treatment in adult patients and <strong>Fast Track designation<\/strong> for alopecia areata treatment.<\/p>\n\n\n\n<p>In August 2022, <strong>Concert Pharmaceuticals<\/strong> announced positive topline results from its second Phase III alopecia areata clinical trial, <strong>THRIVE-AA2,<\/strong> evaluating its oral investigational medicine CTP-543 in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss. The primary efficacy endpoint for <strong>THRIVE-AA2<\/strong> was the percentage of patients achieving an absolute Severity of Alopecia Tool (SALT) score of 20 or less at Week 24 of treatment, which was met with statistical significance in both the 8 mg twice-daily and 12 mg twice-daily dose groups relative to placebo. Alopecia areata treatment with CTP-543 was generally well tolerated.<\/p>\n\n\n\n<p>With the successful completion of our two <strong>THRIVE-AA phase III alopecia areata clinical<\/strong> <strong>trials<\/strong>, <strong>Concert <\/strong>is now moving rapidly to prepare NDA for submission to the US FDA in the first half of 2023. The company is also continuing to advance commercial planning as it positions CTP-543 to potentially enter the marketplace for the large underserved population of <a href=\"https:\/\/www.delveinsight.com\/report-store\/alopecia-areata-epidemiology-forecast\">patients with alopecia areata<\/a>.<\/p>\n\n\n\n<p><strong>In August 2022, Pfizer&#8217;s <\/strong>alopecia areata drug <strong>Ritlecitinib <\/strong>was shown to be linked to a reduction in hair loss in early topline clinical data, setting the stage for a scrap with <strong>Eli Lilly and Incyte<\/strong> in the title fight for a potential blockbuster opportunity for alopecia areata treatment.<\/p>\n\n\n\n<p><strong>Ritlecitinib<\/strong> has met its primary endpoint in <strong>phase II\/III<\/strong> alopecia areata clinical trials. The JAK3\/TEC inhibitor update came months after Eli Lilly and Incyte reported late-phase success in alopecia. <strong>Pfizer\u2019s Ritlecitinib<\/strong> joined <strong>Lilly and Incyte\u2019s Olumiant<\/strong> on the list of drugs to hit the primary endpoint in pivotal alopecia areata clinical trials. Pfizer plans to combine the phase II\/III data with results from an ongoing long-term study to file for approval of <strong>Ritlecitinib<\/strong>. Pfizer has identified Ritlecitinib as one of nine potential blockbusters it aims to <strong>launch by 2025<\/strong>. As Pfizer sees it, Ritlecitinib could <strong>rack up sales<\/strong> of more than <strong>USD 1 billion<\/strong> in alopecia alone. This alopecia areata drug is also in development in vitiligo, rheumatoid arthritis, ulcerative colitis, and Crohn\u2019s disease.<strong>Rosnilimab<\/strong> is another promising <a href=\"https:\/\/www.delveinsight.com\/report-store\/alopecia-areata-market\">alopecia areata treatment<\/a> that is being developed by <strong>ANAPTYSBIO<\/strong>. It is an anti-PD-1 agonist therapeutic antibody undergoing an <strong>AZURE Phase II clinical trial<\/strong> in moderate-to-severe alopecia areata. The company anticipates top-line data in Q1 2023, which is being disclosed in its second quarter 2022 financial results.<\/p>\n\n\n\n<p><strong>Pipeline scenario for alopecia areata treatment (Late-stage therapies)<\/strong><\/p>\n\n\n\n<div>\n<table style=\"border:none; border-collapse:collapse\" width=\"591\">\n\t<colgroup>\n\t\t<col width=\"43\">\n\t\t<col width=\"76\">\n\t\t<col width=\"136\">\n\t\t<col width=\"70\">\n\t\t<col width=\"176\">\n\t\t<col width=\"90\">\n\t<\/colgroup>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#cc223d; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:43px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">S.No<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#cc223d; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:76px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Drug Name<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#cc223d; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:136px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Company<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#cc223d; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:70px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Phase<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#cc223d; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:176px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">MOA<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#cc223d; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:90px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#ffffff\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">ROA<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:43px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">1<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:76px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">CTP-543<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:136px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Concert Pharmaceutical<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:70px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Phase III<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:176px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Janus kinase 1 and 2&nbsp; inhibitor<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:90px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Oral<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:43px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">2<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:76px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Jaktinib<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:136px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Suzhou Zelgen Biopharmaceuticals<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:70px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Phase III<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:176px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Janus kinase 1,2, and&nbsp; 3 inhibitor<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:90px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Oral<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:43px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">3<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:76px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Ritlecitinib<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:136px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Pfizer<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:70px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Phase III<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:176px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">JAK3\/TEC Inhibitor<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:90px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Oral<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:43px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">4<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:76px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">LH-8<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:136px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Legacy Healthcare<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:70px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Phase II\/III<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:176px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Undefined mechanism<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:90px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Topical<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:43px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">5<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:76px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">ANB030<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:136px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">AnaptysBio<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:70px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Phase II<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:176px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Programmed cell death 1 receptor agonists<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:90px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Subcutaneous<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#f2f2f2; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:43px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:700\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">6<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:76px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">SHR0302<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:136px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Reistone Biopharma<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:70px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Phase II<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:176px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Janus kinase 1 inhibitor<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t\t<td style=\"border-bottom:1px solid #808080; vertical-align:top; background-color:#ffffff; padding:7px 7px 7px 7px; border-top:1px solid #808080; border-right:1px solid #808080; border-left:1px solid #808080; width:90px\">\n\t\t\t<p style=\"line-height:1.2; text-align:justify; margin-top:13px\"><span style=\"overflow:hidden\"><span style=\"overflow-wrap:break-word\"><span style=\"font-size:11pt; font-variant:normal; white-space:pre-wrap\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"color:#000000\"><span style=\"font-weight:400\"><span style=\"font-style:normal\"><span style=\"text-decoration:none\">Oral<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/p>\n\t\t\t<\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:39px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong>KOL Views<\/strong><\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><em><strong>Today marks a milestone with the first-ever FDA-approved systemic treatment for Alopecia Areata patients, who face significant challenges every day including limited public knowledge about the disease, a lack of treatment options and social stigma, &#8220;9 said Nicole Friedland, president, and chief executive officer, National Alopecia Areata Foundation (NAAF). &#8220;The approval of OLUMIANT can spark hope for many patients and encourage new treatment conversations with their doctors. NAAF wants more choices for our patient community and with the approval of OLUMIANT, there are now new treatment expectations being established in Alopecia Areata care.<\/strong><\/em><\/p><\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p><em><strong>It is a new era of innovation for developing treatment options for patients with Alopecia Areata, many of whom often suffer physically and mentally with this challenging autoimmune disease,\u201d said Maryanne Senna, MD, Director of the Lahey Hair Loss Clinic of Excellence and clinical investigator of THRIVE-AA2. \u201cThese results are very promising and suggest that CTP-543 has the potential to address important needs for people living with Alopecia Areata.<\/strong><\/em><\/p><\/blockquote>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-changing-alopecia-areata-treatment-trajectory\"><span class=\"ez-toc-section\" id=\"Changing_alopecia_areata_treatment_trajectory\"><\/span><strong>Changing alopecia areata<\/strong> <strong>treatment trajectory<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Alopecia areata has been selected as one of eight new disease areas that it focused on under its <strong>Patient-Focused Drug Development Initiative (PFDDI)<\/strong> in 2016-2017 by US FDA. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Extensive alopecia areata posed a huge therapeutic challenge due to the lack of systemic therapeutics that was FDA-approved for the disease. At first, topical corticosteroids, tacrolimus, cryotherapy, minoxidil, anthralin, or ultraviolet light A combined with oral psoralens (PUVA) were used as the potential alopecia areata treatments, all of which had no robust evidence for their consistent efficacy in alopecia areata. In June 2022, the FDA approved the <a href=\"https:\/\/www.delveinsight.com\/report-store\/alopecia-areata-pipeline-insight\">first oral alopecia areata medication<\/a>, <strong>Olumiant<\/strong>, which blocks the activity of enzymes and the pathway that causes inflammation for alopecia. And more treatment options may be on the way, especially since the FDA cleared the path for a few alopecia areata treatments to get to market faster through its <strong>Breakthrough Therapy designation<\/strong>. This approval will help fulfill a significant unmet need for patients with severe alopecia areata.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09165020\/alopecia-areata-market-dyamics.jpg\" alt=\"Alopecia Areata Market Dynamics\" class=\"wp-image-18854\" width=\"767\" height=\"421\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09165020\/alopecia-areata-market-dyamics.jpg 767w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09165020\/alopecia-areata-market-dyamics-300x165.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09165020\/alopecia-areata-market-dyamics-150x82.jpg 150w\" sizes=\"(max-width: 767px) 100vw, 767px\" \/><figcaption><strong>Alopecia Areata Evolving Market Outlook<\/strong><\/figcaption><\/figure>\n\n\n\n<p>Like many alopecia areata treatments, Olumiant is not without its drawbacks. There are several potential side effects, including GI perforations, respiratory infections, and muscle aches to name a few. These recent regulatory actions have brought attention to the hair loss space, which has ample demand for alopecia areata treatments, but relatively few unique assets in development. When the space is undergoing exciting changes, there is an increased interest in ongoing alopecia areata clinical trials to the potential of a new alopecia areata treatment paradigm. In the coming months, the alopecia areata treatment paradigm is expecting a jump in its treatment options, likely due to the <a href=\"https:\/\/www.delveinsight.com\/blog\/jak-inhibitors-market\">entry of Janus Kinase (JAK) inhibitors<\/a>. Many anti-programmed cell death protein 1 (PD-1) monoclonal antibodies which are potential cancer therapies, are also being investigated for alopecia areata treatment. These investigations are inspired by the use of off-label drugs that target the inflammatory pathway in alopecia areata patients, leading to clinical trials.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Coverage_policies_must_ensure_access_to_FDA-approved_alopecia_areata_treatments\"><\/span><strong>Coverage policies must ensure access to FDA-approved alopecia areata treatments<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Expanding policymakers\u2019 and payers\u2019 view of alopecia areata is vital; thinking of alopecia areata as simply \u201chair loss\u201d diminishes the suffering of many patients living with this disease and minimizes the importance of providing coverage for alopecia areata treatment. The FDA recognizes alopecia areata as a chronic autoimmune disease with a \u201cdebilitating emotional and psychological impact on patients which goes beyond the loss of hair.<\/p>\n\n\n\n<p>Currently, a group of dermatologic conditions (acne, psoriasis, and rosacea) is specifically listed as non-cosmetic by the Centers for Medicare &amp; Medicaid Services for Medicare Part D coverage. As a result, Medicare covers the FDA-approved alopecia areata treatments for these conditions. With several shared characteristics between alopecia areata and these noncosmetic, Medicare-covered <a href=\"https:\/\/www.delveinsight.com\/blog\/companies-investigating-gene-therapy-in-dermatology\">dermatologic conditions<\/a>, there is no question that future FDA-approved alopecia areata treatments should be covered by payers.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Future_perspective_in_the_alopecia_areata_treatment\"><\/span><strong>Future perspective in the alopecia areata treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Treatments for alopecia areata have evolved over the decades from broad and nonspecific alopecia areata therapies to those that are now more targeted and rationally selected. This was achieved using closusingon and communication between clinicians and basic scientists, which resulted in the elucidation and understanding of the unique pathophysiology of alopecia areata. Approval from the US Food and Drug Administration of <strong>Olumiant <\/strong>is a real milestone because no drug has been approved specifically for alopecia areata treatment. There are two other key oral <a href=\"https:\/\/www.delveinsight.com\/blog\/jak-inhibitors-new-lifeline-for-hair-loss-treatment\">JAK inhibitor players<\/a> in alopecia areata:<strong> Pfizer\u2019s ritlecitinib and Concert Pharmaceuticals\u2019 CTP-543 (deuruxolitinib)<\/strong>.&nbsp; AnaptysBio is offering a different mechanism in this space, as it is investigating its anti-PD-1 monoclonal antibody rosnilimab in a placebo-controlled Phase II trial. However, it has been postulated that there is the risk that the anti-PD1 mechanism may not apply to all patients, as JAK is a major pathway in comparison.<\/p>\n\n\n\n<p>Moreover, it has been observed in alopecia areata clinical trials that the disease often comes back when people stop taking the drugs, and some people do not respond to JAK inhibition at all. So a permanent solution is required. One option might be to try to destroy the memory cells that replenish the T-cell population and lower T-cell activity with JAK inhibitors, but it might be possible to clear enough T cells to get rid of the disease altogether. The biggest challenge is going beyond just alopecia areata treatment, and for that, one therapy is not enough. The pathogenesis of alopecia areata is not yet fully understood, but recent investigations of the immune activation in alopecia areata skin reveal Th1\/IFN-\u03b3, as well as Th2, PDE4, IL-23, and IL-9 upregulations. Numerous novel therapeutics are undergoing clinical trials for alopecia areata treatment, emphasizing the potential transformation of the clinical practice of alopecia areata, which is currently lacking. In light of these recent developments, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/alopecia-areata-market\">therapeutic arena of alopecia areata treatments<\/a> is finally getting more exciting. alopecia areata will join the lengthening list of dermatologic diseases with mechanism-targeted drugs, thus changing the face of alopecia areata treatment.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/whitepaper-newsletter\/alopecia-areata-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164543\/Alopecia-Areata-Treatment-Market-1024x256.png\" alt=\"Alopecia Areata Treatment Market\" class=\"wp-image-18847\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164543\/Alopecia-Areata-Treatment-Market-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164543\/Alopecia-Areata-Treatment-Market-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164543\/Alopecia-Areata-Treatment-Market-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164543\/Alopecia-Areata-Treatment-Market-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164543\/Alopecia-Areata-Treatment-Market-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164543\/Alopecia-Areata-Treatment-Market-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164543\/Alopecia-Areata-Treatment-Market.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1662712847616\"><strong class=\"schema-faq-question\"><strong>1. What is alopecia areata?<\/strong><\/strong> <p class=\"schema-faq-answer\">Alopecia areata is a disease that happens when the immune system attacks hair follicles and causes hair loss. Hair follicles are the structures in the skin that form hair. While hair can be lost from any body part, alopecia areata usually affects the head and face.\u00a0<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1662712857077\"><strong class=\"schema-faq-question\"><strong>2. What are the alopecia areata symptoms?<\/strong><\/strong> <p class=\"schema-faq-answer\">Hair loss is among the most common alopecia areata symptoms. Typically, hair falls out in patches on the scalp. These patches are frequently a few centimeters in size or less.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1662712865791\"><strong class=\"schema-faq-question\"><strong>3. What are the alopecia aerate causes?<\/strong><\/strong> <p class=\"schema-faq-answer\">The exact alopecia areata causes are not known. This disorder is thought to be caused by an autoimmune mechanism. Autoimmune disorders occur when the body&#8217;s natural defenses against &#8220;foreign&#8221; or invading organisms begin to attack healthy tissue for unknown reasons. Some cases may be associated with abnormal blood cell reactions to a thyroid protein (thyroglobulin), stomach (parietal) cells, or adrenal cells.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1662712879168\"><strong class=\"schema-faq-question\"><strong>4. What are the current treatments for alopecia areata?<\/strong><\/strong> <p class=\"schema-faq-answer\">Currently, there is no cure and no FDA-approved treatments for alopecia. Thus, the market is completely dominated by off-label drug therapies. Depending on the extent of hair loss and age, a variety of alopecia areata treatment options are available. The main goal of treatment for alopecia areata\u00a0 is to block the immune system attack or stimulate the regrowth of hair.\u00a0<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1662712891671\"><strong class=\"schema-faq-question\"><strong>5. Which companies are working in the alopecia areata market?<\/strong><\/strong> <p class=\"schema-faq-answer\">Leading companies such as Concert Pharmaceutical, Suzhou Zelgen Biopharmaceuticals, Pfizer, Legacy Healthcare, AnaptysBio, Reistone Biopharma, Eli Lilly and Company, Incyte Corporation, Novartis, Bioniz, Rigel Pharmaceuticals, Arcutis Biotherapeutics, LEO Pharma, Arena Pharmaceuticals, HCW Biologics, and others are currently working in the alopecia areata market.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Currently, there is no cure and no FDA-approved treatments for alopecia. Thus, the alopecia areata treatment market is completely dominated by off-label drug therapies. Depending on the extent of hair loss and age, there are a variety of alopecia areata treatment options are available. The main goal of treatment is to block the immune system [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":18843,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[16873,19713,19715,19711,19712,19710,19714,18470],"industry":[17225],"therapeutic_areas":[17237,17227,17234],"class_list":["post-18826","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-alopecia-areata","tag-alopecia-areata-clinical-trials","tag-alopecia-areata-market","tag-alopecia-areata-pipeline","tag-alopecia-areata-therapies","tag-alopecia-areata-treatment","tag-fda-approved-alopecia-areata-treatment","tag-olumiant","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Advancements in the Alopecia Areata Treatment Paradigm<\/title>\n<meta name=\"description\" content=\"Following the changing alopecia areata treatment scenarios, DelveInsight aims to draw attention to newly approved therapy for alopecia areata.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Advancements in the Alopecia Areata Treatment Paradigm\" \/>\n<meta property=\"og:description\" content=\"Following the changing alopecia areata treatment scenarios, DelveInsight aims to draw attention to newly approved therapy for alopecia areata.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-09T12:21:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-29T06:13:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164424\/promising-alopecia-areata-treatment-options.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Advancements in the Alopecia Areata Treatment Paradigm","description":"Following the changing alopecia areata treatment scenarios, DelveInsight aims to draw attention to newly approved therapy for alopecia areata.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options","og_locale":"en_US","og_type":"article","og_title":"Advancements in the Alopecia Areata Treatment Paradigm","og_description":"Following the changing alopecia areata treatment scenarios, DelveInsight aims to draw attention to newly approved therapy for alopecia areata.","og_url":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-09-09T12:21:33+00:00","article_modified_time":"2022-09-29T06:13:09+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164424\/promising-alopecia-areata-treatment-options.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options","url":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options","name":"Advancements in the Alopecia Areata Treatment Paradigm","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164424\/promising-alopecia-areata-treatment-options.png","datePublished":"2022-09-09T12:21:33+00:00","dateModified":"2022-09-29T06:13:09+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Following the changing alopecia areata treatment scenarios, DelveInsight aims to draw attention to newly approved therapy for alopecia areata.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#faq-question-1662712847616"},{"@id":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#faq-question-1662712857077"},{"@id":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#faq-question-1662712865791"},{"@id":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#faq-question-1662712879168"},{"@id":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#faq-question-1662712891671"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164424\/promising-alopecia-areata-treatment-options.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164424\/promising-alopecia-areata-treatment-options.png","width":772,"height":482,"caption":"promising-alopecia-areata-treatment-options"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#faq-question-1662712847616","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#faq-question-1662712847616","name":"1. What is alopecia areata?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Alopecia areata is a disease that happens when the immune system attacks hair follicles and causes hair loss. Hair follicles are the structures in the skin that form hair. While hair can be lost from any body part, alopecia areata usually affects the head and face.\u00a0","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#faq-question-1662712857077","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#faq-question-1662712857077","name":"2. What are the alopecia areata symptoms?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Hair loss is among the most common alopecia areata symptoms. Typically, hair falls out in patches on the scalp. These patches are frequently a few centimeters in size or less.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#faq-question-1662712865791","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#faq-question-1662712865791","name":"3. What are the alopecia aerate causes?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"The exact alopecia areata causes are not known. This disorder is thought to be caused by an autoimmune mechanism. Autoimmune disorders occur when the body's natural defenses against \"foreign\" or invading organisms begin to attack healthy tissue for unknown reasons. Some cases may be associated with abnormal blood cell reactions to a thyroid protein (thyroglobulin), stomach (parietal) cells, or adrenal cells.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#faq-question-1662712879168","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#faq-question-1662712879168","name":"4. What are the current treatments for alopecia areata?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Currently, there is no cure and no FDA-approved treatments for alopecia. Thus, the market is completely dominated by off-label drug therapies. Depending on the extent of hair loss and age, a variety of alopecia areata treatment options are available. The main goal of treatment for alopecia areata\u00a0 is to block the immune system attack or stimulate the regrowth of hair.\u00a0","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#faq-question-1662712891671","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/promising-alopecia-areata-treatment-options#faq-question-1662712891671","name":"5. Which companies are working in the alopecia areata market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Leading companies such as Concert Pharmaceutical, Suzhou Zelgen Biopharmaceuticals, Pfizer, Legacy Healthcare, AnaptysBio, Reistone Biopharma, Eli Lilly and Company, Incyte Corporation, Novartis, Bioniz, Rigel Pharmaceuticals, Arcutis Biotherapeutics, LEO Pharma, Arena Pharmaceuticals, HCW Biologics, and others are currently working in the alopecia areata market.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/09\/09164424\/promising-alopecia-areata-treatment-options-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">alopecia areata<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alopecia Areata clinical trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">alopecia areata market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alopecia Areata pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alopecia Areata therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Alopecia Areata treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">FDA-approved Alopecia Areata treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Olumiant<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">alopecia areata<\/span>","<span class=\"advgb-post-tax-term\">Alopecia Areata clinical trials<\/span>","<span class=\"advgb-post-tax-term\">alopecia areata market<\/span>","<span class=\"advgb-post-tax-term\">Alopecia Areata pipeline<\/span>","<span class=\"advgb-post-tax-term\">Alopecia Areata therapies<\/span>","<span class=\"advgb-post-tax-term\">Alopecia Areata treatment<\/span>","<span class=\"advgb-post-tax-term\">FDA-approved Alopecia Areata treatment<\/span>","<span class=\"advgb-post-tax-term\">Olumiant<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Sep 9, 2022","modified":"Updated on Sep 29, 2022"},"absolute_dates_time":{"created":"Posted on Sep 9, 2022 5:51 pm","modified":"Updated on Sep 29, 2022 11:43 am"},"featured_img_caption":"promising-alopecia-areata-treatment-options","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=18826"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/18826\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/18843"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=18826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=18826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=18826"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=18826"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=18826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}